Skip to content

Inspection Record

Greenwich Rx — FDA 483 Findings

US FDAInspected 2026-09-09Published 2026-10-21 14 findingsAseptic processing and sterility assuranceContamination controlMaterial and supplier controlEquipment and facilityTraining and personnelOther quality system

Inspectors Camerson E MooreThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Smoke studies were not performed under dynamic conditions.

2Contamination control

Personnel infrequently changed and sanitized gloves to prevent contamination.

3Material and supplier control

Compounding with components, containers or other materials that have not been verified to assure that they do not contribute endotoxin contamination that may be objectionable given the product's intended use.

4Aseptic processing and sterility assurance

Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

5Equipment and facility

The facility design was observed to allow the influx of lesser quality air into a classified area containing higher quality air.

6Training and personnel

Personnel donned gowning apparel improperly, in a way that may have caused the gowning apparel to become contaminated.

7Contamination control

Your firm produced drugs while construction was underway in an adjacent area without adequate controls to prevent contamination of the production environment and product.

8Training and personnel

Personnel were observed moving quickly in a critical area or in an area immediately adjacent to a critical area likely causing disrnption ofunidirectional airflow.

9Contamination control

Microbial contamination was present in the ISO 5 area and areas adjacent to production areas.

10Aseptic processing and sterility assurance

Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.

11Other quality system

Inadequate <Redacted B4> testing on <Redacted B4> used to sterilize drug products.

12Aseptic processing and sterility assurance

Use of ingredients not intended for pharmaceutical use in sterile drug production.

13Other quality system

A pattern of frequent or acute pressure reversals was observed from areas of less clean air to areas of higher air cleanliness.

14Other quality system

Lack of disinfection of supplies at each transition from areas of lower quality air to areas of higher quality air.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-21. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Greenwich Rx company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.